Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortive CorpFTV · Entity 3303 | Director | June 04, 2019 | June 05, 2019 |
| Moderna, Inc.MRNA · Entity 2025 | Director | June 27, 2019 | June 28, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortive Corp
Report date June 04, 2019 · Filed June 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,565 |
Ending reported balance
After 2019-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-06-04 · Grant · Acquired 1,105 · Balance 5,860 F1: On June 4, 2019, the Issuer granted to the Reporting Person restricted stock units ("Annual Grant RSUs") of the Issuer in the amount indicated as portion of the annual equity grant made to the Reporting Person. Since the Annual Grant RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Annual Grant RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2020 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. Row 2 · 2019-06-04 · Grant · Acquired 705 · Balance 6,565 F2: On June 4, 2019, the Issuer granted to the Reporting Person restricted stock units ("Deferral RSUs") of the Issuer in the amount indicated, based on a 20-day average price of $79.52, pursuant to deferral election made by the Reporting Person of $56,000 in annual retainer that would otherwise have been paid in cash. Since the Deferral RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Deferral RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2020 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first year following the Reporting Person's retirement from the Board of Directors of the Issuer. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.77 · Expires 2029-06-04 | Direct | 3,340 |
Reported balance
After 2019-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-04 · Grant · Acquired 3,340 · Balance 3,340 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 4, 2019, the Issuer granted to the Reporting Person restricted stock units ("Annual Grant RSUs") of the Issuer in the amount indicated as portion of the annual equity grant made to the Reporting Person. Since the Annual Grant RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Annual Grant RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2020 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer.
F2: On June 4, 2019, the Issuer granted to the Reporting Person restricted stock units ("Deferral RSUs") of the Issuer in the amount indicated, based on a 20-day average price of $79.52, pursuant to deferral election made by the Reporting Person of $56,000 in annual retainer that would otherwise have been paid in cash. Since the Deferral RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Deferral RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2020 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first year following the Reporting Person's retirement from the Board of Directors of the Issuer.
Moderna, Inc.
Report date June 27, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.34 · Expires 2029-06-27 | Direct | 54,660 |
Reported balance
After 2019-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-27 · Grant · Acquired 54,660 · Balance 54,660 F1: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2019 Filed Jun 28, 2019 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 54,660 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001127602-19-023031 · form4.xml · derivative · entry 1 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,660 Underlying: Common Stock · 54,660 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 19:28 UTC | Fortive Corp FTV · Entity 3303 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,340 | $0.00 Strike: $77.77 | $0.00 |
DisclosureSEC source: 0001659166-19-000146 · wf-form4_155977729713268.xml · derivative · entry 3 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,340 Underlying: Common Stock · 3,340 shares Expires 2029-06-04 Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 19:28 UTC | Fortive Corp FTV · Entity 3303 | GrantCommon Stock | 705 | $79.52 | $56,061.60 |
DisclosureSEC source: 0001659166-19-000146 · wf-form4_155977729713268.xml · nonDerivative · entry 2 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,565 F2 · shares: On June 4, 2019, the Issuer granted to the Reporting Person restricted stock units ("Deferral RSUs") of the Issuer in the amount indicated, based on a 20-day average price of $79.52, pursuant to deferral election made by the Reporting Person of $56,000 in annual retainer that would otherwise have been paid in cash. Since the Deferral RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Deferral RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2020 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first year following the Reporting Person's retirement from the Board of Directors of the Issuer. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 19:28 UTC | Fortive Corp FTV · Entity 3303 | GrantCommon Stock | 1,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001659166-19-000146 · wf-form4_155977729713268.xml · nonDerivative · entry 1 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,860 F1 · shares: On June 4, 2019, the Issuer granted to the Reporting Person restricted stock units ("Annual Grant RSUs") of the Issuer in the amount indicated as portion of the annual equity grant made to the Reporting Person. Since the Annual Grant RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Annual Grant RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2020 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries G Preferred Stock · Derivative | 4,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030864 · doc4.xml · derivative · entry 2 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionCommon Stock | 4,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030864 · doc4.xml · nonDerivative · entry 1 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 16:15 UTC | Fortive Corp FTV · Entity 3303 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,520 | $0.00 Strike: $74.30 | $0.00 |
DisclosureSEC source: 0001659166-18-000156 · wf-form4_152840253461104.xml · derivative · entry 3 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,520 Underlying: Common Stock · 3,520 shares Expires 2028-06-05 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 16:15 UTC | Fortive Corp FTV · Entity 3303 | GrantCommon Stock | 745 | $75.50 | $56,247.50 |
DisclosureSEC source: 0001659166-18-000156 · wf-form4_152840253461104.xml · nonDerivative · entry 2 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,755 F2 · shares: On June 5, 2018, the Issuer granted to the Reporting Person restricted stock units ("Deferral RSUs") of the Issuer in the amount indicated, based on a 20-day average price of $75.50, pursuant to deferral election made by the Reporting Person of $56,000 in annual retainer that would otherwise have been paid in cash. Since the Deferral RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Deferral RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2019 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first year following the Reporting Person's retirement from the Board of Directors of the Issuer. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 16:15 UTC | Fortive Corp FTV · Entity 3303 | GrantCommon Stock | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001659166-18-000156 · wf-form4_152840253461104.xml · nonDerivative · entry 1 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,010 F1 · shares: On June 5, 2018, the Issuer granted to the Reporting Person restricted stock units ("Annual Grant RSUs") of the Issuer in the amount indicated as portion of the annual equity grant made to the Reporting Person. Since the Annual Grant RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The Annual Grant RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2019 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 17:02 UTC | Fortive Corp FTV · Entity 3303 | GrantDirector Stock Option (Right to Buy) · Derivative | 4,240 | $0.00 Strike: $63.20 | $0.00 |
DisclosureSEC source: 0001659166-17-000156 · wf-form4_149695573174948.xml · derivative · entry 2 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,240 Underlying: Common Stock · 4,240 shares Expires 2027-06-06 Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 17:02 UTC | Fortive Corp FTV · Entity 3303 | GrantCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001659166-17-000156 · wf-form4_149695573174948.xml · nonDerivative · entry 1 Ruiz Israel · CIK 0001670805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,850 F1 · shares: On June 6, 2017, the Issuer granted to the Reporting Person restricted stock units (RSUs) of the Issuer in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date or the date of the Issuer's 2018 annual meeting of the stockholders, but the underlying shares will not be issued until the earlier of the Reporting Person's death or the first day of the seventh month following the Reporting Person's retirement from the Board of Directors of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.